Biocryst Pharmaceuticals Inc.

NASDAQ:BCRX   3:59:58 PM EDT
14.33
+0.08 (+0.56%)
Other Pre-Announcement

Biocryst Q2 Net Loss Of $0.32 Per Share

Published: 08/04/2022 11:55 GMT
Biocryst Pharmaceuticals Inc. (BCRX) - Biocryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones.
Biocryst Pharmaceuticals Inc - for Three Months Ended June 30, 2022, Total Revenues Were $65.5 Million, Compared to $50.0 Million in Q2 of 2021.
Biocryst Pharmaceuticals Inc - Net Loss for Q2 of 2022 Was $58.9 Million, Or $0.32 per Share.
Biocryst Pharmaceuticals Inc - Co Expects Full Year 2022 Net Orladeyo Revenue to Be Between $255 Million and $265 Million.